Clinical Trials Browser

Leukemia × Gemcitabine × Plasma cell × Clear all

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT00477035 2017-01-11

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Phase 1 Completed

22 enrolled

Other hematologic neoplasmPlasma cell

Leukemia, Multiple Myeloma

NCT00410982 2016-06-03

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

Phase 1 Completed

145 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

Clinical Trials

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies